Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI).

Dunbar GC, Inglis F, Kuchibhatla R, Sharma T, Tomlinson M, Wamsley J.

J Psychopharmacol. 2007 Mar;21(2):171-8. Erratum in: J Psychopharmacol. 2008 Aug;22(6):698.

PMID:
17329297
2.

Central nicotinic cholinergic systems: a role in the cognitive dysfunction in attention-deficit/hyperactivity disorder?

Potter AS, Newhouse PA, Bucci DJ.

Behav Brain Res. 2006 Dec 15;175(2):201-11. Epub 2006 Nov 1. Review.

PMID:
17081628
3.

Antisense knockdown of the rat alpha7 nicotinic acetylcholine receptor produces spatial memory impairment.

Curzon P, Anderson DJ, Nikkel AL, Fox GB, Gopalakrishnan M, Decker MW, Bitner RS.

Neurosci Lett. 2006 Dec 13;410(1):15-9. Epub 2006 Oct 20.

PMID:
17055644
4.

Impact of psychometrically defined deficits of executive functioning in adults with attention deficit hyperactivity disorder.

Biederman J, Petty C, Fried R, Fontanella J, Doyle AE, Seidman LJ, Faraone SV.

Am J Psychiatry. 2006 Oct;163(10):1730-8.

PMID:
17012683
5.

The worldwide prevalence of ADHD: is it an American condition?

Faraone SV, Sergeant J, Gillberg C, Biederman J.

World Psychiatry. 2003 Jun;2(2):104-13.

6.

SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia.

Pichat P, Bergis OE, Terranova JP, Urani A, Duarte C, Santucci V, Gueudet C, Voltz C, Steinberg R, Stemmelin J, Oury-Donat F, Avenet P, Griebel G, Scatton B.

Neuropsychopharmacology. 2007 Jan;32(1):17-34. Epub 2006 Aug 23.

7.

Brain nicotinic acetylcholine receptors: native subtypes and their relevance.

Gotti C, Zoli M, Clementi F.

Trends Pharmacol Sci. 2006 Sep;27(9):482-91. Epub 2006 Jul 31. Review.

PMID:
16876883
8.

Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship.

Wishka DG, Walker DP, Yates KM, Reitz SC, Jia S, Myers JK, Olson KL, Jacobsen EJ, Wolfe ML, Groppi VE, Hanchar AJ, Thornburgh BA, Cortes-Burgos LA, Wong EH, Staton BA, Raub TJ, Higdon NR, Wall TM, Hurst RS, Walters RR, Hoffmann WE, Hajos M, Franklin S, Carey G, Gold LH, Cook KK, Sands SB, Zhao SX, Soglia JR, Kalgutkar AS, Arneric SP, Rogers BN.

J Med Chem. 2006 Jul 13;49(14):4425-36.

PMID:
16821801
9.

(R)-3'-(3-methylbenzo[b]thiophen-5-yl)spiro[1-azabicyclo[2,2,2]octane-3,5'-oxazolidin]-2'-one, a novel and potent alpha7 nicotinic acetylcholine receptor partial agonist displays cognitive enhancing properties.

Tatsumi R, Fujio M, Takanashi S, Numata A, Katayama J, Satoh H, Shiigi Y, Maeda J, Kuriyama M, Horikawa T, Murozono T, Hashimoto K, Tanaka H.

J Med Chem. 2006 Jul 13;49(14):4374-83.

PMID:
16821797
10.

Selective alpha7 nicotinic acetylcholine receptor ligands.

Mazurov A, Hauser T, Miller CH.

Curr Med Chem. 2006;13(13):1567-84. Review. Erratum in: Curr Med Chem. 2007;14(14):1593.

PMID:
16787204
11.

ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study.

Wilens TE, Verlinden MH, Adler LA, Wozniak PJ, West SA.

Biol Psychiatry. 2006 Jun 1;59(11):1065-70. Epub 2006 Feb 23.

PMID:
16499880
12.

The reinforcing effects of nicotine and stimulant medication in the everyday lives of adult smokers with ADHD: A preliminary examination.

Gehricke JG, Whalen CK, Jamner LD, Wigal TL, Steinhoff K.

Nicotine Tob Res. 2006 Feb;8(1):37-47.

PMID:
16497598
13.

Effects of transdermal nicotine on attention in adult non-smokers with and without attentional deficits.

Poltavski DV, Petros T.

Physiol Behav. 2006 Mar 30;87(3):614-24. Epub 2006 Feb 7.

PMID:
16466655
14.
15.

Acute effects of nicotine on attention and response inhibition.

Bekker EM, Böcker KB, Van Hunsel F, van den Berg MC, Kenemans JL.

Pharmacol Biochem Behav. 2005 Nov;82(3):539-48. Epub 2005 Dec 19.

PMID:
16360813
16.

Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization.

Levin ED, McClernon FJ, Rezvani AH.

Psychopharmacology (Berl). 2006 Mar;184(3-4):523-39. Epub 2005 Oct 12. Review.

PMID:
16220335
17.

Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of young adults.

Kollins SH, McClernon FJ, Fuemmeler BF.

Arch Gen Psychiatry. 2005 Oct;62(10):1142-7.

PMID:
16203959
18.

Atomoxetine and stroop task performance in adult attention-deficit/hyperactivity disorder.

Faraone SV, Biederman J, Spencer T, Michelson D, Adler L, Reimherr F, Seidman L.

J Child Adolesc Psychopharmacol. 2005 Aug;15(4):664-70.

PMID:
16190797
19.

Unraveling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and cognitive modulation of signal detection.

Sarter M, Hasselmo ME, Bruno JP, Givens B.

Brain Res Brain Res Rev. 2005 Feb;48(1):98-111. Review.

PMID:
15708630
20.

Neuronal nicotinic receptors: from structure to pathology.

Gotti C, Clementi F.

Prog Neurobiol. 2004 Dec;74(6):363-96. Review.

PMID:
15649582

Supplemental Content

Support Center